- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Amber Specialty Pharmacy Chosen to Dispense Aduhelm
The specialty pharmacy is licensed in all 50 states.
Amber Specialty Pharmacy, a subsidiary of Hy-Vee Inc that located in Omaha, Neb., has announced that it will begin dispensing Aduhelm (aducanumab-avwa), Biogen’s and Eisai’s therapy to treat Alzheimer’s disease.
Amber Specialty Pharmacy is licensed in all 50 states, as well as Puerto Rico. “We are committed to partnering with prescribers to support caregivers, families, and patients as they navigate a devastating diagnosis like Alzheimer’s,” Kristin Williams, president of Amber Specialty Pharmacy and chief health officer of Hy-Vee, said in a statement.
Biogen and Eisai announced recently that the FDA approved updated prescribing information for Aduhelm to specify its use in patients with mild Alzheimer’s disease. Biogen officials said this was done to clarify the patient population that the therapy was studied in.
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
Humira Biosimilars Have a Slow Uptake, Finds Samsung Bioepis Report
April 8th 2024Caps on Medicare Part D cost sharing as a result of the Inflation Reduction Act, could reduce members’ financial incentive for switching to a biosimilar, suggests the newest Samsung Bioepis Quarterly Biosimilar Market Report.
